Kintor to Start US Trial of Baldness Treatment
July 12, 2021 at 05:27 AM EDT
Suzhou 's Kintor Pharma will start a US Phase II trial of its treatment for male pattern baldness. Pyrilutamide is a small molecule topical androgen receptor antagonist that inhibits both the androgen receptor and androgen in hair follicle sebaceous glands, thereby treating androgenetic alopecia and acne. The trial is Kintor's fifth US clinical study. Kintor's China Phase II trial of pyrilutamide is nearing its conclusion, with top-line data expected sometime in Q3 of this year. More details.... Stock Symbol: (HK:9939)
